As of Feb 17
| +0.1067 / +24.07%|
The 1 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 1.50, with a high estimate of 1.50 and a low estimate of 1.50. The median estimate represents a +172.73% increase from the last price of 0.55.
The current consensus among 1 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.